Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.61 |
| ▸ | CTSS | P25774 | 6/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | BCL2 | P10415 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9929938 | 1.00 | CTSK (0.61) | CTSKCTSSATMCTSBCTSL | |
| SCHEMBL598263 | 1.00 | CTSK (0.61) | CTSKCTSSATMCTSBCTSL | |
| SCHEMBL7094 | 0.92 | ATM (0.62) | CTSKCTSSATMCTSBCTSL | |
| SCHEMBL1094506 | 0.92 | ATM (0.62) | CTSKCTSSATMCTSBCTSL | |
| SCHEMBL390555 | 0.92 | ATM (0.62) | CTSKCTSSATMCTSBCTSL | |
| SCHEMBL16945132 | 0.89 | CTSS (0.60) | CTSKCTSSATMCTSBCTSL | |
| SCHEMBL18995190 | 0.88 | CTSK (0.54) | CTSKCTSSATMCTSBCTSL | |
| SCHEMBL14274169 | 0.88 | PPARG (0.58) | CTSKCTSSATMCTSBCTSL | |
| SCHEMBL1912623 | 0.87 | CTSL (0.50) | CTSKCTSSCTSBCTSLACE | |
| SCHEMBL30867 | 0.85 | CTSS (0.59) | CTSKCTSSATMCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980833-B2 | Tubulysine derivatives | R&D-BIOPHARMACEUTICALS GMBH (DE) | 2015-03-17 | — | — | US | disclosed |
| EP-2148886-B1 | TUBULYSINE DERIVATIVES | R & D BIOPHARMACEUTICALS GMBH (DE) | 2014-02-19 | — | — | EP | disclosed |
| EP-2532673-A2 | Tubulysine derivatives | R & D Biopharmaceuticals Gmbh (DE) | 2012-12-12 | — | — | EP | disclosed |
| US-20120129779-A1 | TUBULYSINE DERIVATIVES | R&D-BIOPHARMACEUTICALS GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| WO-2008138561-A1 | TUBULYSINE DERIVATIVES | R & D BIOPHARMACEUTICALS GMBH (DE) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129779-A1 | TUBULYSINE DERIVATIVES | GLS, TPX2, HKDC1 | CTSK 232/4885CTSS 471/4885ATM 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.